글로벌 진료소 감염성 질환 진단 시장 – 2031년까지의 산업 동향 및 예측

Point of Care 감염성 질환 진단 시장 분석 및 규모

진료 시점 감염병 진단 시장은 전 세계 의료 환경에서 신속하고 정확한 진단 솔루션에 대한 수요가 증가함에 따라 상당한 성장을 목격하고 있습니다. 이러한 진단은 특히 전염을 예방하고 환자 결과를 개선하기 위해 신속한 개입이 중요한 감염병의 경우 시기적절한 질병 탐지 및 관리를 가능하게 하는 데 중요합니다. 이 시장은 분자 진단, 면역 검정 및 신속한 항원 검사를 포함한 진단 기술의 발전으로 뒷받침되며, 이를 통해 환자의 진료 시점 또는 그 근처에서 빠르고 효율적인 검사가 가능합니다. POC IDD 솔루션은 의료 서비스 제공자에게 감염을 신속하게 진단하고, 적절한 치료를 시작하고, 실시간으로 환자 반응을 모니터링할 수 있는 기능을 제공하여 중앙 실험실의 부담을 줄이고 의료 효율성을 개선합니다.

글로벌 진료소 감염병 진단 시장 규모는 2023년에 22억 달러로 평가되었으며, 2031년까지 64억 2천만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

보고 범위 및 시장 세분화       

시장 정의

진료소 감염병 진단은 일반적으로 중앙 실험실이 아닌 진료소, 의사 사무실 또는 현장과 같은 의료 시설 내에서 환자의 위치 또는 그 근처에서 수행되는 진단 검사 를 말합니다. 이러한 검사는 빠르고 정확한 결과를 제공하도록 설계되어 의료 제공자가 즉각적인 치료 결정을 내릴 수 있습니다. POC IDD 기술은 분자 진단 , 면역 검정 및 신속 진단 검사(RDT)를 포함한 다양한 방법을 포함합니다 .                          

Point of Care 감염성 질환 진단 시장 역학

운전자

• 빠른 진단에 대한 수요

의료 환경에서 신속한 진단 솔루션에 대한 수요가 증가하는 것은 치료 시점에서 감염성 질병을 신속하게 감지해야 하는 시급한 필요성 때문입니다. 이러한 솔루션을 통해 의료 서비스 제공자는 적절한 치료를 신속하게 시작하여 환자 결과를 개선하고 커뮤니티 내 전파 위험을 줄일 수 있습니다. 신속한 진단 검사(RDT), 분자 진단 및 항원 검사는 인플루엔자, 결핵 및 COVID-19와 같은 새로운 발병과 같은 감염을 진단하는 데 중요합니다. 이러한 수요는 즉각적인 진단이 질병 관리 및 공중 보건 결과에 상당한 영향을 미칠 수 있는 응급실, 진료소 및 외딴 지역에서 특히 중요합니다.

• 감염병 유행 증가

The global rise in infectious diseases, exacerbated by factors such as population growth, urbanization, and international travel, underscores the importance of adopting point-of-care diagnostics for infectious diseases. Infectious disease outbreaks, including pandemics like COVID-19, highlight the necessity for rapid and accurate diagnostic tools that can quickly identify pathogens and facilitate timely intervention strategies. POC IDD solutions play a crucial role in surveillance, early detection, and containment efforts, empowering healthcare systems to effectively manage disease spread and mitigate public health crises through targeted interventions and preventive measures.

Opportunities

• Development of Multiplex Assays

Advancements in multiplex assay technologies are transforming Point of Care Infectious Disease Diagnostic (POC IDD) devices. These assays allow simultaneous detection of multiple pathogens or biomarkers in a single test, boosting diagnostic efficiency and broadening the applications of POC IDD devices. By consolidating testing procedures and cutting turnaround times, multiplex assays help healthcare providers quickly make informed decisions, especially during complex clinical situations or outbreaks where identifying several pathogens swiftly is crucial. This innovation not only enhances diagnostic accuracy but also improves how healthcare resources are used and creates new market opportunities.  

• Integration with Digital Health Platforms  

Linking POC IDD devices with digital health platforms opens up new possibilities for healthcare delivery. By connecting diagnostic data with electronic health records (EHRs), telemedicine platforms, and real-time monitoring systems, healthcare providers can streamline workflows, enhance patient care, and enable remote consultations. This digital integration makes it easier to transmit diagnostic results, improving access to healthcare services, particularly in remote or underserved areas where traditional infrastructure may be lacking, creating new opportunities for the point of care infectious disease diagnostics market.

Restraints/Challenges

• Regulatory Challenges

Stringent regulatory requirements for the approval and commercialization of POC IDD devices present significant challenges for manufacturers and market entry. Compliance with diverse regulatory frameworks across different regions necessitates comprehensive testing, validation, and documentation, adding complexity and time to the product development lifecycle. Regulatory barriers can impede innovation and market access, particularly for novel technologies or devices seeking global deployment.  

• Accuracy and Reliability Concerns

Concerns regarding the accuracy and reliability of POC IDD devices compared to laboratory-based assays remain a critical consideration for healthcare providers and regulatory bodies. Variability in test performance under different environmental conditions, operator proficiency, and specimen quality can impact diagnostic accuracy and reliability, potentially influencing clinical decision-making.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In October 2023, QIAGEN achieved CE certification for its IVD kit and automated testing platform, NeuMoDx. This development significantly boosted the company’s revenue and market share
• In May 2023, Danaher Corporation introduced the Dxl 9000 Access Immunoassay Analyzer capable of processing up to 215 tests per hour. This launch expanded the company’s offerings in point-of-care diagnostics
• In May 2023, BD announced 510k clearance for its BD Kiestra Methicillin-resistant Staphylococcus aureus (MRSA) imaging application, which incorporates AI software. This innovation reduces test result turnaround times by automating the labor-intensive process of identifying bacterial growth traditionally done using petri dishes

Point of Care Infectious Disease Diagnostics Market Scope

The market is segmented on the basis of product, technology, application, and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• Consumables
• Instruments
• Software and Services

Technology

• Lateral Flow
• Agglutination Assays
• Flow-Through
• Solid Phase

Application

• HIV
• Tropical Disease
• Liver Disease
• Inflammatory Disease
• Respiratory Disease
• Hospital Associated Infections
• Sexual Health Disorders

End User

• Hospitals
• Healthcare Centers
• Laboratories
• Independent Diagnostic Centers
• Home Care Settings

Point of Care Infectious Disease Diagnostics Market Regional Analysis/Insights

The market is analyzed and market size insights and trends are provided by country, product, technology, application, and end user as referenced above.

The countries covered in the market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina, and rest of South America.

North America is expected to dominate the market due to a significant rise in the adoption of testing instruments in hospitals to meet the growing demand for point-of-care diagnostics for various infectious diseases. The availability of robust healthcare and medical facilities, coupled with heightened awareness and the presence of skilled professionals, further consolidates its position as the dominant market.

Asia-Pacific is expected to witness significant growth during the forecast period due to ongoing investments in healthcare infrastructure and other medical advancements. This growth is characterized by expanding access to healthcare facilities, increased investment in medical technologies, and enhanced healthcare services. These developments contribute significantly to the region's emerging prominence in the healthcare sector.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.

Competitive Landscape and Point of Care Infectious Disease Diagnostics Market Share Analysis

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

시장에서 활동하는 주요 기업은 다음과 같습니다.

• 지멘스 헬스키니어스 AG(독일)
• Trivitron Healthcare(인도)
• F. 호프만-라 로슈 유한회사(스위스)
• 애벗(미국)
• Quest Diagnostics Incorporated(미국)
• BD(미국)
• Chembio Diagnostics Inc. (미국)
• 트리니티 바이오텍(아일랜드)
• 카디널 헬스(미국)
• Bio-Rad Laboratories Inc. (미국)
• bioMérieux SA(프랑스)
• Thermo Fisher Scientific Inc. (미국)
• 퀴델 코퍼레이션(미국)
• OJ-Bio Limited(영국)

SKU-63670